Download PDF
Thromb Haemost 1993; 70(02): 270-272
DOI: 10.1055/s-0038-1649564
Original Articles
Clinical Studies
Schattauer GmbH Stuttgart

Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease

M Morfini
1   The Hematology Department and Hemophilia Center, University of Florence, Italy
,
P M Mannucci
2   The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy
,
P M Tenconi
2   The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy
,
G Longo
1   The Hematology Department and Hemophilia Center, University of Florence, Italy
,
M G Mazzucconi
3   The Department of Biopathology (Hematology Section), University of Rome, Italy
,
F Rodeghiero
4   The Hemophilia and Thrombosis Center, Vicenza, Italy
,
N Ciavarella
5   The Hemophilia and Thrombosis Center, Bari, Italy
,
V De Rosa
6   The Angiology Division and Hemophilia Center, University of Bologna, Italy
,
A Arter
7   Baxter Healthcare, Hyland Division, Glendale, California, USA
› Author Affiliations
Further Information

Publication History

Received 15 December 1992

Accepted after revision 19 February 1993

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A monoclonally-purified factor VIII (FVIII) concentrate, containing little von Willebrand factor (vWF), was infused to 11 patients with severe von Willebrand disease and unmeasurable levels of plasma vWF. In comparison with the historical data obtained infusing hemophiliacs in the same conditions, monoclonally-purified FVIII had a significantly shorter half-life and faster clearance from plasma but similar in vivo recovery and volume of distribution. Two additional patients with severe von Willebrand disease were also infused with recombinant FVIII totally devoid of vWF. Half-life was very short and in vivo recovery low, with a larger volume of distribution than for monoclonally-purified FVIII. We conclude that in patients with severe von Willebrand disease the small amounts of vWF contained in the monoclonally-purified FVIII concentrate are not sufficient to stabilize infused FVIII, nor to support the normal circulation of endogenous FVIII that these patients produce at a normal rate.

 

  • References

  • 1 Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988; 40: 205-214
    PubMedGoogle Scholar
  • 2 Morfini M, Rafanelli D, Filimberti E, Cinotti S, Piazza E, Longo G, Rossi FerriniP. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thromb Res 1989; 56: 169-178
    CrossrefPubMedGoogle Scholar
  • 3 Morfini M, Mannucci PM, Longo G, Cinotti S, Messori A. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. Thromb Res 1991; 61: 285-290
    CrossrefPubMedGoogle Scholar
  • 4 Kasper CK, Kim HC, Gomperts ED, Smith KJ, Salzman PM, Tipping D, Miller R, Montgomery RM. In vivo recovery and survival of monoclonal antibody purified factor VIII concentrates. Thromb Haemostas 1991; 66: 730-733
    PubMedGoogle Scholar
  • 5 Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on post transfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390-404
    CrossrefPubMedGoogle Scholar
  • 6 Messori A, Longo G, Matucci M, Morfini M, Rossi FerriniP. Clinical pharmacokinetics of factor VIII in patients with classic hemophilia. Clin Pharmacokinet 1987; 13: 365-380
    CrossrefPubMedGoogle Scholar
  • 7 Tuddenham EGD, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PBA. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human hemophilia A and von Willebrand’s disease. Br J Haematol 1982; 52: 259-267
    CrossrefPubMedGoogle Scholar
  • 8 Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III. Ann Hematol 1992; 65: 253-259
    CrossrefPubMedGoogle Scholar
  • 9 Morfini M, Longo G, Messori A, White G, Mannucci PM. and the Recombinate Study Group Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemophil M). Thromb Haemostas 1992; 68: 433-435
    PubMedGoogle Scholar